Hervé M, de La Rocque F, Bouhanna A, Albengres E, Reinert P
Service de pédiatrie, centre hospitalier intercommunal, Créteil, France.
Arch Pediatr. 1998 May;5(5):503-9. doi: 10.1016/S0929-693X(99)80314-5.
One to 10% of treatments using betalactams, particularly synthetic penicillin, are complicated by allergic reactions, usually cutaneous, and not easily imputable to immunologic sensitization in children.
The aim of this study was to identify, using cutaneous and biological tests, those from a group of 112 children suspected of amoxicillin allergy (evidenced by rash) who were actually sensitized, and to confirm the absence of allergy in others by an oral provocation test (OPT) associated to a long-term survey. The cutaneous tests were made by prick test and intra-dermo reaction (IDR) with Allergopen and with amoxicillin or amoxicillin + clavulanic acid. The biological tests included examination for penicillin and amoxicillin antibodies by using various techniques including enzyme-linked immunosorbent assay (ELISA) immunoglobulin G (IgG) and IgE, FARR, radioallergo sorbent test (RAST) and a histaminoliberation. When these tests were negative, an OPT with the suspected antibiotic was subsequently performed.
Thirty-nine children (36.4%) confidently presented at least one positive cutaneous test (38 Allergopen, ten amoxicillin); 25 biological tests were positive (16 ELISA IgE, one ELISA IgG and eight histaminolibarations), seven times with negative cutaneous test. Forty-five children were judged to be sensitized to amoxicillin, with only one who subsequently took amoxicillin again. Among the 67 others, 52 received an OPT, six of them with moderate cutaneous reactions. Fifty-one (45.5%) children were allergic and 46 (41%) were allowed to take amoxicillin again; 17 did, one of them with a benign cutaneous reaction.
Efficacy and safety of this type of investigation seems clear; it will have to be confirmed by other studies.
使用β-内酰胺类药物(尤其是合成青霉素)进行治疗时,有1%至10%会出现过敏反应并发症,通常为皮肤过敏,且在儿童中不易归因于免疫致敏。
本研究的目的是通过皮肤和生物学检测,从一组112名疑似阿莫西林过敏(表现为皮疹)的儿童中识别出真正致敏的儿童,并通过与长期调查相关的口服激发试验(OPT)来确认其他儿童不存在过敏情况。皮肤检测采用用变应原提取物、阿莫西林或阿莫西林+克拉维酸进行点刺试验和皮内反应(IDR)。生物学检测包括使用多种技术检测青霉素和阿莫西林抗体,这些技术包括酶联免疫吸附测定(ELISA)免疫球蛋白G(IgG)和IgE、荧光偏振免疫测定(FARR)、放射变应原吸附试验(RAST)以及组胺释放试验。当这些检测结果为阴性时,随后对疑似抗生素进行OPT。
39名儿童(36.4%)明确出现至少一项阳性皮肤检测结果(38项变应原提取物检测阳性,10项阿莫西林检测阳性);25项生物学检测结果为阳性(16项ELISA IgE阳性,1项ELISA IgG阳性,8项组胺释放试验阳性),其中7次皮肤检测结果为阴性。45名儿童被判定对阿莫西林致敏,其中只有1名儿童随后再次服用了阿莫西林。在其他67名儿童中,52名接受了OPT,其中6名出现中度皮肤反应。51名(45.5%)儿童过敏,46名(41%)儿童被允许再次服用阿莫西林;17名儿童再次服用了阿莫西林,其中1名出现良性皮肤反应。
这类调查的有效性和安全性似乎很明确;这还有待其他研究加以证实。